Raphael Pharmaceutical (RAPH) Net Income towards Common Stockholders (2020 - 2024)
Raphael Pharmaceutical's (RAPH) quarterly Net Income towards Common Stockholders came in at -$394000.0 in Q4 2024, down 394.03% year-on-year from $134000.0 in Q1 2024, and down 23.51% quarter-over-quarter from -$319000.0 in Q3 2024.
Raphael Pharmaceutical (RAPH) Net Income towards Common Stockholders (2020 - 2024) Analysis & Trends
Raphael Pharmaceutical has disclosed Net Income towards Common Stockholders across 5 years of filings, most recently posting -$394000.0 for Q4 2024.
- Net Income towards Common Stockholders for Q4 2024 came in at -$394000.0, down 394.03% year-over-year; the trailing twelve-month figure through Sep 2025 was -$394000.0 (up 59.84% YoY), and the FY2025 annual result was -$1.2 million, up 17.5% from the prior year.
- Net Income towards Common Stockholders came in at -$394000.0 for Q4 2024 at Raphael Pharmaceutical, down from -$319000.0 in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $134000.0 in Q4 2023 to a low of -$1.4 million in Q3 2022.
- The 5-year median for Net Income towards Common Stockholders is -$389500.0 (2021), against an average of -$454944.4.
- Across the five-year window, Net Income towards Common Stockholders jumped 112.14% in 2023 and sank 394.03% in 2024, its largest moves.
- Raphael Pharmaceutical's Net Income towards Common Stockholders stood at -$227000.0 in 2020, then tumbled by 152.86% to -$574000.0 in 2021, then slumped by 92.33% to -$1.1 million in 2022, then jumped by 112.14% to $134000.0 in 2023, then tumbled by 394.03% to -$394000.0 in 2024.
- The last three Net Income towards Common Stockholders figures came in at -$394000.0 (Q4 2024), -$319000.0 (Q3 2024), and -$249000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.97 Bn | 36.23 Bn | 1.97 Bn | 366.00 Mn |
| 2 | Zoetis | 33.59 Bn | 31.65 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Neurocrine Biosciences | 16.10 Bn | 14.78 Bn | 800.70 Mn | 197.90 Mn |
| 5 | Aurora Cannabis | 15.56 Bn | 15.47 Bn | 21.72 Mn | 4.43 Mn |
| 6 | Elanco Animal Health | 12.04 Bn | 11.61 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.36 Bn | 6.84 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Lantheus Holdings | 6.74 Bn | 6.24 Bn | 230.92 Mn | 118.42 Mn |
| 9 | Liquidia | 6.27 Bn | 6.04 Bn | 121.79 Mn | 52.88 Mn |
| 10 | Raphael Pharmaceutical | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -394,000.00 |
| Sep 30, 2024 | -319,000.00 |
| Jun 30, 2024 | -249,000.00 |
| Mar 31, 2024 | -547,000.00 |
| Dec 31, 2023 | 134,000.00 |
| Sep 30, 2023 | -729,000.00 |
| Jun 30, 2023 | -419,000.00 |
| Mar 31, 2023 | -258,000.00 |
| Dec 31, 2022 | -1.10 Mn |
| Sep 30, 2022 | -1.43 Mn |
| Jun 30, 2022 | -612,000.00 |
| Mar 31, 2022 | -175,000.00 |
| Dec 31, 2021 | -574,000.00 |
| Sep 30, 2021 | -418,000.00 |
| Jun 30, 2021 | -385,000.00 |
| Mar 31, 2021 | -252,000.00 |
| Dec 31, 2020 | -227,000.00 |
| Sep 30, 2020 | -235,000.00 |